Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Use Reduces Risk of Early-Onset Colorectal Cancer in Patients with Type 2 Diabetes-Mellitus (T2DM)

被引：0
|
作者：
Olasehinde, Temitope [1 ]
Cooper, Gregory [1 ]
Perez, Jaime A. [1 ]
机构：
[1] Case Western Reserve Univ, Univ Hosp, Cleveland Med Ctr, Dept Neurol, Cleveland, OH USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001031256.48901.46
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S472
引用
收藏
页码：S329 / S330
页数：2
相关论文
共 50 条
  • [31] Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
    Harris, Kira B.
    McCarty, Delilah J.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (01) : 3 - 18
  • [32] TTP054, a Novel, Orally-Available Glucagon-like Peptide-1 (GLP-1) Agonist, Lowers HbA1c in Subjects with Type 2 Diabetes Mellitus (T2DM)
    Gustavson, Stephanie
    Grimes, Imogene
    Valcarce, Carmen
    Burstein, Aaron
    Mjalli, Adnan
    DIABETES, 2014, 63 : A41 - A42
  • [33] Improving Glucagon-like Peptide-1 Dynamics in Patients With Type 2 Diabetes Mellitus
    Freeman, Jeffrey S.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2012, 112 (01): : S2 - S6
  • [34] Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
    Bensignor, Megan O.
    Wolf, Jack M.
    Rudser, Kyle D.
    Kelly, Aaron S.
    Arslanian, Silva
    DIABETES OBESITY & METABOLISM, 2022, 24 (07): : 1380 - 1384
  • [35] Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review
    Parab, Panah
    Chaudhary, Priti
    Mukhtar, Sonia
    Moradi, Ali
    Kodali, Athri
    Okoye, Chiugo
    Klein, Dhadon
    Mohamoud, Iman
    Olanisa, Olawale O.
    Hamid, Pousette
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [36] Preserved Inhibitory Effect of Glucagon-Like Peptide-1 (GLP-1) on Glucagon Secretion in Type 2 Diabetes Mellitus
    Hare, Kristine J.
    Knop, Filip K.
    Asmar, Meena
    Larsen, Steen
    Madsbad, Sten
    Holst, Jens J.
    Vilsboll, Tina
    DIABETES, 2009, 58 : A372 - A372
  • [37] Efpeglenatide Glucagon-like peptide 1 (GLP-1) receptor agonist Treatment for type 2 diabetes
    Reid, J.
    Rana, K.
    Segel, S. A.
    Sheikh-Ali, M.
    Choksi, R. R.
    Goldfaden, R. F.
    DRUGS OF THE FUTURE, 2019, 44 (06) : 435 - 441
  • [38] Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
    Gutzwiller, JP
    Drewe, J
    Göke, B
    Schmidt, H
    Rohrer, B
    Lareida, J
    Beglinger, C
    AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1999, 276 (05) : R1541 - R1544
  • [39] Use of SGLT2 Inhibitors and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Australian Primary Care Patients with Type 2 Diabetes Mellitus (T2DM) Stratified by CKD Status
    Wallace, Hannah
    Wick, James
    Ketema, Daniel Bekele
    Neuen, Brendon Lange
    Jardine, Meg
    Lin Jialing
    Nelson, Craig L.
    Pearson, Sallie
    Peiris, David
    Woodward, Mark
    Ronksley, Paul E.
    Gallagher, Martin P.
    Kotwal, Sradha S.
    Jun, Min
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [40] ALBIGLUTIDE Glucagon-Like Peptide GLP-1 Receptor Agonist Treatment of Type 2 Diabetes
    Rosenstock, Julio
    Stewart, Murray W.
    DRUGS OF THE FUTURE, 2010, 35 (09) : 701 - 712
12345